☆ 4.4 Review

Immunotherapy approaches for rare pediatric solid tumors: advances and future directions

CURRENT OPINION IN PEDIATRICS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients

Lihua Yu et al.

Summary: The study evaluated the safety and efficacy of using chimeric antigen receptor (CAR) disialoganglioside 2 (GD2)-specific (4SCAR-GD2) T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients. Results showed that 4SCAR-GD2 T-cell therapy demonstrated antitumor effect and manageable toxicities, indicating its potential to benefit children with refractory and/or recurrent NB.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

GD2-CART cell therapy for H3K27M-mutated diffuse midline gliomas

Robbie G. Majzner et al.

Summary: Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs) are lethal pediatric tumors of the central nervous system. GD2-directed chimeric antigen receptor (CAR) T cells show promising preclinical efficacy. Four patients with H3K27M-mutated DIPG or spinal cord DMG were treated with GD2-CAR T cells and showed clinical and radiographic improvement.

NATURE (2022)

添加到收藏夹

Article Oncology

Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells

Talar Tokatlian et al.

Summary: This study developed a dual-receptor system that can target mesothelin expressed in both tumor and normal tissues, reducing the risk of serious inflammation caused by the treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Review Oncology

TCR-T Immunotherapy: The Challenges and Solutions

Yating Liu et al.

Summary: TCR-T cell therapy is a potential cellular immunotherapy for cancer treatment. However, its efficacy in solid tumors is lower compared to hematological malignancies. This article discusses the barriers and strategies affecting the efficacy of TCR-T cell immunotherapy in solid tumors.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Cancer Immunoediting in the Era of Immuno-oncology

Matthew M. Gubin et al.

Summary: Cancer immunoediting is a dynamic process in which the immune system controls and shapes cancer. It leads to reduced immunogenicity of tumors and the establishment of an immunosuppressive microenvironment. However, current research on cancer immunoediting has mainly focused on immune selection and neoantigen loss, neglecting other mechanisms that modify tumor immunogenicity. Understanding cancer immunoediting is important for understanding immunotherapy resistance and finding ways to overcome it.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study

Byoung Chul Cho et al.

Summary: The combination of tiragolumab and atezolizumab showed promising efficacy and safety as first-line treatment for NSCLC, with improved objective response rate and progression-free survival compared to placebo plus atezolizumab.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.

Navin R. Pinto et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

Jaime Gallego Perez-Larraya et al.

Summary: This study investigated the use of oncolytic virus DNX-2401 in pediatric patients with diffuse intrinsic pontine glioma (DIPG). The results showed that treatment with DNX-2401 led to changes in T-cell activity and reduction or stabilization of tumor size in some patients, but also caused adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Immunology

Interplay between Solid Tumors and Tumor Microenvironment

Seung-Jin Kim et al.

Summary: This article discusses the process of tumors adapting to adverse environments through communication with neighboring cells. Understanding the physiology of these tumors and their interaction with the tumor environment can help in developing promising tumor treatment strategies.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Oncology

A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children?s Oncology Group Study ADVL1412 br

Kara L. Davis et al.

Summary: This study is a phase I/II clinical trial of nivolumab plus ipilimumab in children and young adults with recurrent/refractory solid tumors. The results of the study show that this combination therapy is relatively safe and can improve response rates in some tumors.

CLINICAL CANCER RESEARCH (2022)

添加到收藏夹

Review Immunology

Clinical cancer immunotherapy: Current progress and prospects

Chenglong Liu et al.

Summary: Immune checkpoint therapy utilizing PD-1 antibodies has demonstrated significant clinical value and therapeutic potential, although it is not without limitations such as immune-related adverse events, cytokine storm, and low response rates. This review discusses the basic classification, research progress, and limitations of cancer immunotherapy, as well as providing insights into the development of new anticancer immunotherapy strategies through the analysis of resistance mechanisms and combination therapy.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Review Oncology

Natural killer cells in antitumour adoptive cell immunotherapy

Tamara J. Laskowski et al.

Summary: This review provides an overview of NK cell-based immunotherapies, discussing strategies to increase NK cell cytotoxicity and persistence and highlighting the current challenges and future opportunities for the design of next-generation NK cell therapies.

NATURE REVIEWS CANCER (2022)

添加到收藏夹

Review Oncology

B7-H3: An Attractive Target for Antibody-based Immunotherapy

Filippos Kontos et al.

Summary: B7-H3, as a potential target for antibody-based immunotherapy, is overexpressed in malignant tissues and associated with poor prognosis. Although the receptor for B7-H3 remains unknown, various antibody-based strategies targeting B7-H3-expressing cancer cells have been developed, demonstrating potent antitumor activity in preclinical models. Ongoing clinical trials are evaluating the safety and efficacy of these strategies in patients, with the hope of enhancing the therapeutic efficacy of tumor immunity.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article

CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions

Saar Gill et al.

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting (2021)

添加到收藏夹

Article Oncology

Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery

Dalia Haydar et al.

Summary: The study identified that B7-H3 and GD2 are highly expressed CAR target antigens in different pediatric brain tumor types, while other antigens have lower expression. High-grade gliomas expressed HLA class I, but other tumor subtypes had lower detectable expression. B7-H3 was chosen as the target for CAR T-cell therapy, showing promising antitumor activity in experiments.

NEURO-ONCOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma

Babak Moghimi et al.

Summary: The study highlights the importance of developing gated systems for predicting clinical toxicity of CAR T cells in solid tumors. By utilizing murine and human CAR-T cells specific for tumor antigens, the researchers were able to generate a GD2-B7H3 CAR-T with improved metabolic fitness and efficacy in controlling neuroblastoma growth in preclinical models. This innovative approach shows promising results in suppressing neuroblastoma with minimal adverse effects.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Oncology

Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4

Vijay G. Bhoj et al.

Summary: GFR alpha 4 has been identified as a potential target for CAR T cell therapy in MTC, as it is highly expressed in MTC and can trigger cytotoxicity and cytokine production. CAR T cells constructed with GFR alpha 4-specific scFvs show promising results in vitro and in vivo, supporting GFR alpha 4 as a promising target for MTC therapy.

MOLECULAR THERAPY-ONCOLYTICS (2021)

添加到收藏夹

Review Oncology

Combination strategies to maximize the benefits of cancer immunotherapy

Shaoming Zhu et al.

Summary: This review discusses the relationship between cancer immune response and resistance mechanisms to immunotherapy, as well as provides a comprehensive overview of the latest clinical status and FDA-approved combination therapies. It also covers therapies targeting cytokines, immunotherapy, virotherapy, innate immune modifiers, and cancer vaccines, as well as insights from the 2020 China Immuno-Oncology Workshop.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi et al.

Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

Oncolytic virotherapy as immunotherapy

Alan Melcher et al.

SCIENCE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis

Sabina Kaczanowska et al.

Summary: By utilizing genetically engineered myeloid cells to deliver IL-12, immune suppression in the premetastatic niche can be reversed, resulting in improved survival and reduced metastatic and primary tumor burden in tumor-bearing mice.

CELL (2021)

添加到收藏夹

Article Oncology

B7-H3 as a Target for CAR-T Cell Therapy in Skull Base Chordoma

Cheng Long et al.

Summary: This study identified B7-H3 as a potential target for CAR-T cell therapies against skull base chordomas. Immunohistochemical analysis of clinical samples revealed positive expression of B7-H3 in a subset of chordoma samples. B7-H3 targeted CAR-T cells demonstrated significant antitumor effects in vitro, including suppression of tumor spheroid formation, CAR-T cell activation, and cytokine secretion.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas

G. K. Friedman et al.

Summary: The study conducted a phase 1 trial of G207 in children and adolescents with recurrent or progressive supratentorial brain tumors, showing an acceptable adverse-event profile and evidence of responses. G207 was able to convert immunologically cold tumors to hot.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Review Immunology

Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors

Lele Miao et al.

Summary: Chimeric antigen receptor (CAR) T-cell immunotherapy has shown significant progress in hematologic malignancies, but its efficacy in solid tumors is limited due to the complex biological characteristics of solid tumors. Research indicates that CAR-T cells play a better role in addressing obstacles in solid tumors, suggesting potential for improved efficacy with further study and development.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

Abdul Rafeh Naqash et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Sandra P. D'Angelo et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Phase II study of nivolumab and ipilimumab in children and young adults with INI1-negative cancers.

Suzanne J. Forrest et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesus G. Berdeja et al.

Summary: The study aimed to evaluate the safety and clinical activity of cilta-cel in patients with relapsed or refractory multiple myeloma, and the results showed that cilta-cel treatment achieved good efficacy and safety with short treatment duration, deep response, and long duration of response.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis

Nicholas A. Vitanza et al.

Summary: The use of engineered medium-length CAR spacers enhances the therapeutic efficacy of HER2-specific CAR T cells in medulloblastoma models, and initial clinical trial results show that repetitive locoregional dosing of these CAR T cells in children and young adults with CNS tumors is feasible and well tolerated, leading to localized immune activation in the CNS.

NATURE MEDICINE (2021)

添加到收藏夹

Article Immunology

A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells

Lindsay Jones Talbot et al.

Summary: The study developed an orthotopic, spontaneously metastasizing osteosarcoma model for evaluating the anti-tumor activity of CAR T cell therapy, resulting in significant survival advantages.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Review Cell Biology

Evolution of CD8+ T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer

Yimo Sun et al.

Summary: Engineered TCR-T cell therapy has revolutionized the treatment of human cancer by targeting tumor antigen-specific adaptable cellular products. However, challenges such as low TCR avidity, off-target toxicities, and target antigen loss have limited the efficacy of TCR-T therapy for solid tumors. Further research is needed to address these limitations and improve the safety and efficacy of TCR-T therapies.

CELLS (2021)

添加到收藏夹

Review Immunology

Tumor-infiltrating lymphocytes in the immunotherapy era

Sterre T. Paijens et al.

Summary: The success of cancer immune checkpoint blockade has led to increased interest in tumor-infiltrating lymphocytes (TILs) across different cancer types. Single-cell analysis has revealed high cellular heterogeneity in TILs, with distinct patterns of immune activation and exhaustion. While TIL distributions are similar across tumor types, their responses to immunotherapy vary, highlighting the complexity of tumor-immune interactions.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

添加到收藏夹

Article Oncology

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

David S. Hong et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial

Birgit Geoerger et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab A Phase 2 Clinical Trial

Ciara M. Kelly et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Acquired Resistance to Immune Checkpoint Inhibitors

Adam J. Schoenfeld et al.

CANCER CELL (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors

Johanna Theruvath et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors

Joshua D. Bernstock et al.

HUMAN GENE THERAPY (2020)

添加到收藏夹

Article Medicine, General & Internal

CAR-T design: Elements and their synergistic function

Jayapriya Jayaraman et al.

EBIOMEDICINE (2020)

添加到收藏夹

Review Cell Biology

Macrophage Modification Strategies for Efficient Cell Therapy

Anastasiya S. Poltavets et al.

CELLS (2020)

添加到收藏夹

Review Oncology

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Bassel Nazha et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Oncolytic viruses for cancer immunotherapy

Otto Hemminki et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Review Oncology

EZH2: a novel target for cancer treatment

Ran Duan et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma

Meenakshi Hegde et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Medicine, General & Internal

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson et al.

LANCET (2020)

添加到收藏夹

Review Oncology

TIGIT in cancer immunotherapy

Joe-Marc Chauvin et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

添加到收藏夹

Article Cell Biology

Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma

Karin Straathof et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

添加到收藏夹

Article Biotechnology & Applied Microbiology

First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial

Keri A. Streby et al.

MOLECULAR THERAPY (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4

Shuang Qin et al.

MOLECULAR CANCER (2019)

添加到收藏夹

Article Oncology

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

Robbie G. Majzner et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Review Pathology

Adoptive cellular therapies: the current landscape

Maartje W. Rohaan et al.

VIRCHOWS ARCHIV (2019)

添加到收藏夹

Review Immunology

The Intriguing History of Cancer Immunotherapy

Paula Dobosz et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

Current Progress in CAR-T Cell Therapy for Solid Tumors

Shuo Ma et al.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2019)

添加到收藏夹

Review Pathology

SMARCB1-deficient Tumors of Childhood: A Practical Guide

Bruce R. Pawel

PEDIATRIC AND DEVELOPMENTAL PATHOLOGY (2018)

添加到收藏夹

Article Anatomy & Morphology

Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy

Liisa Chang et al.

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2018)

添加到收藏夹

Review Immunology

Driving CARs on the uneven road of antigen heterogeneity in solid tumors

Nan Chen et al.

CURRENT OPINION IN IMMUNOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Oncology

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259 T Cells in Synovial Sarcoma

Sandra P. D'Angelo et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Review Pediatrics

Pediatric Cancer Immunotherapy: Opportunities and Challenges

Mary Frances Wedekind et al.

PEDIATRIC DRUGS (2018)

添加到收藏夹

Editorial Material Immunology

From Cancer Immune Surveillance to Cancer Immunoediting: Birth of Modern Immuno-Oncology

Wolf H. Fridman

JOURNAL OF IMMUNOLOGY (2018)

添加到收藏夹

Review Oncology

Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy

Eric K. Ring et al.

CLINICAL CANCER RESEARCH (2017)

添加到收藏夹

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Biotechnology & Applied Microbiology

The basics of CAR T design and challenges in immunotherapy of solid tumors Ovarian cancer as a model

Xuequn Xu et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)

添加到收藏夹

Review Oncology

Pre-metastatic niches: organ-specific homes for metastases

Hector Peinado et al.

NATURE REVIEWS CANCER (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

Prospects for gene-engineered T cell immunotherapy for solid cancers

Christopher A. Klebanoff et al.

NATURE MEDICINE (2016)

添加到收藏夹

Meeting Abstract Oncology

Genetically engineered NY-ESO-1-specific T cells in HLA-A2+patients with synovial sarcoma

Melinda S. Merchant et al.

CANCER RESEARCH (2015)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Oncolytic viruses: a new class of immunotherapy drugs

Howard L. Kaufman et al.

NATURE REVIEWS DRUG DISCOVERY (2015)

添加到收藏夹

Article Oncology

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Paul F. Robbins et al.

CLINICAL CANCER RESEARCH (2015)

添加到收藏夹

Article Oncology

The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints

Nicolas J. Llosa et al.

CANCER DISCOVERY (2015)

添加到收藏夹

Article Cell Biology

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

Prasad S. Adusumilli et al.

SCIENCE TRANSLATIONAL MEDICINE (2014)

添加到收藏夹

Article Oncology

Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy

Matthew D. Vesely et al.

RENAISSANCE OF CANCER IMMUNOTHERAPY (2013)

添加到收藏夹

Review Biochemistry & Molecular Biology

Hallmarks of Cancer: The Next Generation

Douglas Hanahan et al.

CELL (2011)

添加到收藏夹

Article Oncology

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Paul F. Robbins et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

添加到收藏夹

Article Gastroenterology & Hepatology

Microsatellite Instability in Colorectal Cancer

C. Richard Boland et al.

GASTROENTEROLOGY (2010)

添加到收藏夹

Article Public, Environmental & Occupational Health

The Occurrence of Rare Cancers in US Adults, 1995-2004

Robert T. Greenlee et al.

PUBLIC HEALTH REPORTS (2010)

添加到收藏夹

Review Oncology

Mesothelin targeted cancer immunotherapy

Raffit Hassan et al.

EUROPEAN JOURNAL OF CANCER (2008)

添加到收藏夹

Review Oncology

Progress in Childhood Cancer: 50 Years of Research Collaboration, a Report From the Children's Oncology Group

Mouro O'Leary et al.

SEMINARS IN ONCOLOGY (2008)

添加到收藏夹

Review Medicine, Research & Experimental

Immune surveillance of tumors

Jeremy B. Swann et al.

JOURNAL OF CLINICAL INVESTIGATION (2007)

添加到收藏夹

Article Oncology

The challenge of very rare tumours in childhood: The Italian TREP project

Andrea Ferrari et al.

EUROPEAN JOURNAL OF CANCER (2007)

添加到收藏夹

Article Pathology

Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors

JM Bourgeois et al.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.